Treatment of Relapsed/Refractory Multiple Myeloma-Reference-Cited by-同舟云学术

Treatment of Relapsed/Refractory Multiple Myeloma

Published:2009-04 Issue:2 Volume:46 Page:143-157
ISSN:0037-1963
Container-title:Seminars in Hematology
language:en
Short-container-title:Seminars in Hematology

Author:

Kastritis Efstathios,Palumbo Antonio,Dimopoulos Meletios A.

Publisher

Elsevier BV

Subject

Hematology

Reference112 articles.

1. International uniform response criteria for multiple myeloma;Durie;Leukemia,2006

2. High-dose glucocorticoid treatment of resistant myeloma;Alexanian;Ann Intern Med,1986

3. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma;Richardson;N Engl J Med,2005

4. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of a North American phase III study (MM-009) [abstract];Weber;J Clin Oncol (Meeting Abstracts),2006

5. Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a phase 3 study (MM-010) [abstract];Dimopoulos;ASH Annual Meeting Abstracts,2005

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Partial immunoparesis contributes to risk of early infections in patients with multiple myeloma;Translational Cancer Research;2021-12

2. Melflufen for relapsed and refractory multiple myeloma;Expert Opinion on Investigational Drugs;2020-09-29

3. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1–2 study;The Lancet Haematology;2020-05

4. New Insights in Anti-Angiogenesis in Multiple Myeloma;International Journal of Molecular Sciences;2018-07-12

5. N-terminal B-type natriuretic peptide (NT-proBNP) is associated with disease severity in multiple myeloma;European Journal of Clinical Investigation;2018-02-27